| Document Date: 2014-11-06 23:49:15
Open Document File Size: 247,85 KBShare Result on Facebook
Company Pfizer Australia / Molec cular Pty Ltd / Vysis ALK Break Apart FISH Probe Kit / Abbott Australasia Pty Ltd / Abbott Molecular Diagnostics / Pffizer Austrralia Pty Ltd / using the Vysis ALK Break Apart FISH Probe Kit / / Country Australia / / Currency USD / / Event FDA Phase / / IndustryTerm proposed clinical management algorithm / clinical algorithm / proposed clinical algorithm / clinical management algorithm / in-vitro diagnostic medical device / clinical management / / MedicalCondition advanced disease / disease / NSCLC / IHC positive NSCLC tumours / metastasis / tumour / SCLC / lung cancer / both squamous cell carcinoma / nonsmall cell lung cancer / non-small cell lung cancer / squamous cell carcinomas / anaplastic lymphoma kinase / smalll cell lun ng cancer / adenocarcinoma / / MedicalTreatment chemotherapy / / MusicGroup Yes / / Organization Protocol Advisory Sub Committee / Medicare / / Person Fluorescent / Category / / Position consultant physician / / Product ALK / EGFR / / ProvinceOrState Western Australia / Queensland / South Australia / New South Wales / Victoria / / Region South Australia / South Wales / Western Australia / / Technology testing 9/20 algorithm / clinical algorithm / proposed clinical management algorithm / final Decision Analytical Protocol / antibodies / hybridization / chemotherapy / submission Algorithm / proposed clinical algorithm / clinical management algorithm / final Decision Analytic Protocol / /
SocialTag |
Microsoft Word[removed]PSD-ALK testing for crizotinib-accessible (D14[removed]docx